Redeye comments on W5’s announcement that Daniel Hopstadius will resign as CEO due to personal reaso...
Redeye comments on the warrants TO2.
Redeye finds that the clinical study of fostrox in liver cancer is progressing favourably with some ...
Redeye comments on Energy Save’s (ES) Q2’23/24 report, showing weaker sales and profitability than e...
Redeye adjusts its estimates and valuation following the SEK425m directed share issue and the acquis...
Endomines updated its mineral resource estimate for Korvilansuo.
Scandinavian Astor Group (”Astor Group” eller ”bolaget”) meddelade den 15 december att dotterbolaget...
Redeye is impressed by today’s mega-deal of SEK1.55 bn for Smart Eye.
Sprint Bioscience (Sprint) meddelar att Deciphera har valt att returnera VPS34-hämmarprogrammet utan...
Den virtuella satellitsnätsoperatören Wyld Networks (”Wyld”) har påbörjat leverans av moduler vilket...
Primärt mål uppnått Vid en utökad analys, av de åtta patienter med misstänkt endometrios som deltog ...
Mendus has presented positive survival data for the ADVANCE II trial with its lead asset, vididencel...
This Tuesday, between 15:00-18:00, Egetis Therapeutics hosts a Capital Markets Day.
Redeye endorses this morning’s news that IRLAB has submitted a request for an end-of-phase II meetin...
Acquires Svensk Direktreklam for SEK 350m (fully paid in cash).
Redeye gives an initial comment on the news that Saniona has announced a rights issue of around to S...
Biovica’s right issue secures SEK 100m, and the number of shares will increase from 45.
Imlifidase shows a superior ability reducing donor-specific antibodies (DSAs) in the phase 2 study i...
Vitrolife’s CEO Bronwyn Brophy came across as executive and resourceful during her first CMD at Vitr...
edyoutec AB (”edyoutec” eller ”Bolaget”), tidigare Wicket Gaming, har nu påbörjat transformationen m...